.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,871,759

« Back to Dashboard
Patent 8,871,759 protects ZEPATIER and is included in one NDA.

This patent has thirty-three patent family members in twenty-seven countries.

Summary for Patent: 8,871,759

Title:Inhibitors of hepatitis C virus replication
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. ##STR00001##
Inventor(s): Coburn; Craig A. (Royersford, PA), Ludmerer; Steven W. (North Wales, PA), Liu; Kun (Edison, NJ), Wu; Hao (Shanghai, CN), Soll; Richard (San Diego, CA), Zhong; Bin (Shanghai, CN), Zhu; Jian (Shanghai, CN)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/260,684
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp Dohme
ZEPATIER
elbasvir; grazoprevir
TABLET;ORAL208261-001Jan 28, 2016RXYes8,871,759► subscribeYY TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,871,759

PCT Information
PCT FiledMarch 25, 2010PCT Application Number:PCT/US2010/028653
PCT Publication Date:September 30, 2010PCT Publication Number: WO2010/111483

Non-Orange Book Patents for Patent: 8,871,759

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,090,661Inhibitors of hepatitis C virus replication► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,871,759

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Morocco33209► subscribe
South Korea20130140219► subscribe
South Korea101387274► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc